ID: ALA2115269

Max Phase: Preclinical

Molecular Formula: C7H15NO3

Molecular Weight: 161.20

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H]1C[C@H](N)[C@@H](O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C7H15NO3/c1-3-2-4(8)6(10)7(11)5(3)9/h3-7,9-11H,2,8H2,1H3/t3-,4+,5-,6-,7-/m1/s1

Standard InChI Key:  SRXWNPSUBPQINT-IECVIRLLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 161.20

Molecular Weight (Monoisotopic): 161.1052

AlogP: -1.56

#Rotatable Bonds: 0

Polar Surface Area: 86.71

Molecular Species: BASE

HBA: 4

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.97

CX Basic pKa: 9.19

CX LogP: -1.69

CX LogD: -3.46

Aromatic Rings: 0

Heavy Atoms: 11

QED Weighted: 0.35

Np Likeness Score: 2.03

References

1. Ogawa S, Mori M, Takeuchi G, Doi F, Watanabe M, Sakata Y..  (2002)  Convenient synthesis and evaluation of enzyme inhibitory activity of several N-alkyl-, N-phenylalkyl, and cyclic isourea derivatives of 5a-carba-alpha-DL-fucopyranosylamine.,  12  (20): [PMID:12270152] [10.1016/s0960-894x(02)00627-3]

2. Ogawa S, Watanabe M, Maruyama A, Hisamatsu S..  (2002)  Synthesis of an alpha-fucosidase inhibitor, 5a-carba-beta-L-fucopyranosylamine, and fucose-type alpha- and beta-DL-valienamine unsaturated derivatives.,  12  (5): [PMID:11858994] [10.1016/s0960-894x(02)00004-5]

3. Ogawa S, Watanabe M, Maruyama A, Hisamatsu S..  (2002)  Synthesis of an alpha-fucosidase inhibitor, 5a-carba-beta-L-fucopyranosylamine, and fucose-type alpha- and beta-DL-valienamine unsaturated derivatives.,  12  (5): [PMID:11858994] [10.1016/s0960-894x(02)00004-5]

Source

Source(1):

• Scientific Literature